Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11447-11454

  Monu, Ngozi ^a   Frey, Alan B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE ZAP 70; PROTEIN P56; PROTEIN TYROSINE PHOSPHATASE SHP 1; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; COLON CARCINOMA; CONTROLLED STUDY; CYTOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHROMIUM; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; NITRITES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, ANTIGEN, T-CELL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UREA;

EID: 37049011210     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1441     Document Type: Article

References (25)

1. Schreiber H, Wu TH, Nachman J, et al. Immunodominance and tumor escape. Semin Cancer Biol 2002;12:25-31.
2. Disis ML, Calenoff E, McLaughlin G, et al. Existent Tcell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
3. Pittet MJ, Speiser DE, Valmori D, et al. Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol 2001;1:1235-47.
4. Whiteside TL, Parmiani G. Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 1994;39:15-21.
5. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-16.
6. Prevost-Blondel A, Zimmermann C, Stemmer C, et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998;161:2187-94.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
8. Frey AB, Monu N. Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol 2006;79:652-62.
9. Koneru M, Schaer D, Monu N, et al. Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol 2005;174:1830-40.
10. Radoja S, Rao TD, Hillman D, et al. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J Immunol 2000;164:2619-28.
11. Radoja S, Saio M, Frey AB. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol 2001;166:6074-83.
12. Radoja S, Saio M, Schaer D, et al. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol 2001;167:5042-51.
13. Koneru M, Monu N, Schaer D, et al. Defective adhesion in tumor infiltrating CD8+ T cells. J Immunol 2006;176:6103-11.
14. Saio M, Radoja S, Marino M, et al. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol 2001;167:5583-93.
15. Misko TP, Schilling RJ, Salvemini D, et al. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993;214:11-6.
16. Schimke RT. The importance of both synthesis and degradation in the control of arginase levels in rat liver. J Biol Chem 1964;239:3808-17.
17. Kilgore NE, Carter JD, Lorenz U, et al. Cutting edge: dependence of TCR antagonism on Src homology 2 domain-containing protein tyrosine phosphatase activity. J Immunol 2003;170:4891-5.
18. Chen D, Iijima H, Nagaishi T, et al. Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol 2004;172:3535-43.
19. Wang N, Li Z, Ding R, et al. Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J Biol Chem 2006;281:21878-83.
20. Bronte V, Serafini P, Mazzoni A, et al. L-Arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003;24:302-6.
21. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
22. Chiang GG, Sefton BM. Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase. J Biol Chem 2001;276:23173-8.
23. Watts JD, Sanghera JS, Pelech SL, et al. Phosphorylation of serine 59 of p56lck in activated T cells. J Biol Chem 1993;268:23275-82.
24. Winkler DG, Park I, Kim T, et al. Phosphorylation of Ser-42 and Ser-59 in the N-terminal region of the tyrosine kinase p56lck. Proc Natl Acad Sci U S A 1993;90:5176-80.
25. Nitschke L. The role of CD22 and other inhibitory coreceptors in B-cell activation. Curr Opin Immunol 2005;17:290-7.